New rationales for using TGFbeta inhibitors in radiotherapy

References

• Ahmed M M, Alcock R A, Chendil D, Dey S, Das A, Venkatasubbarao K, Mohiuddin M, Sun L, Strodel W E, Freeman J W. Restoration of transforming growth factor-beta signaling enhances radiosensitivity by altering the Bcl-2/Bax ratio in the p53 mutant pancreatic cancer cell line MIA PaCa-2. Journal of Biological Chemistry 2002; 277: 2234–2246
   PubMed Web of Science ®Google Scholar
• Akhurst R J. TGF-{beta} antagonists: Why suppress a tumor suppressor?. Journal of Clinical Investigation 2002; 109: 1533–1536
   PubMed Web of Science ®Google Scholar
• Annes J P, Munger J S, Rifkin D B. Making sense of latent TGF{beta} activation. Journal of Cell Science 2003; 116: 217–224
   PubMed Web of Science ®Google Scholar
• Anscher M S, Crocker I R, Jirtle R L. Transforming growth factor b1 expression in irradiated liver. Radiation Research 1990; 122: 77–85
   PubMed Web of Science ®Google Scholar
• Anscher M S, Kong F, Murase T, Jirtle R L. Short communication: Normal tissue injury after cancer therapy is a local response exacerbated by an endocrine effect of TGFb. British Journal of Radiology 1995; 68: 331–333
   PubMed Web of Science ®Google Scholar
• Anscher M S, Peters W P, Reisenbichler H, Petros W P, Jirtle R L. Transforming growth factor b as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. New England Journal of Medicine 1993; 328: 1592–1598
   PubMed Web of Science ®Google Scholar
• Anscher M S, Thrasher B, Rabbani Z, Teicher B, Vujaskovic Z. Antitransforming growth factor-[beta] antibody 1D11 ameliorates normal tissue damage caused by high-dose radiation. International Journal of Radiation Oncology, Biology, Physics 2006; 65: 876–881
   PubMed Web of Science ®Google Scholar
• Bakkenist C J, Kastan M B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003; 421: 499–506
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay A, Agyin J K, Wang L, Tang Y, Lei X, Story B M, Cornell J E, Pollock B H, Mundy G R, Sun L-Z. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-{beta} Type I receptor kinase inhibitor. Cancer Research 2006; 66: 6714–6721
   PubMed Web of Science ®Google Scholar
• Barcellos-Hoff M H. Radiation-induced transforming growth factor b and subsequent extracellular matrix reorganization in murine mammary gland. Cancer Research 1993; 53: 3880–3886
   PubMed Web of Science ®Google Scholar
• Barcellos-Hoff M H. A novel redox mechanism for TGF-beta activation. Molecular Biology of the Cell 1994; 5: 139a
   Google Scholar
• Barcellos-Hoff M H. How do tissues respond to damage at the cellular level? The role of cytokines in irradiated tissues. Radiation Research 1998; 150: S109–120
   PubMed Web of Science ®Google Scholar
• Barcellos-Hoff M H, Derynck R, Tsang ML-S, Weatherbee J A. Transforming growth factor-b activation in irradiated murine mammary gland. Journal of Clinical Investigation 1994; 93: 892–899
   PubMed Web of Science ®Google Scholar
• Barcellos-Hoff M H, Dix T A. Redox-mediated activation of latent transforming growth factor-b1. Molecular Endocrinology 1996; 10: 1077–1083
   PubMed Web of Science ®Google Scholar
• Barcellos-Hoff M H, Park C, Wright E G. Radiation and the microenvironment – tumorigenesis and therapy. Nature Review Cancer 2005; 5: 867–875
   PubMed Web of Science ®Google Scholar
• Brown P D, Wakefield L M, Levinson A D, Sporn M B. Physiochemical activation of recombinant latent transforming growth factor-betas 1, 2, and 3. Growth Factors 1990; 3: 35–43
   PubMed Web of Science ®Google Scholar
• Derynck R, Akhurst R J, Balmain A. TGF-b signaling in tumor suppression and cancer progression. Nature Genetics 2001; 29: 117–129
   PubMed Web of Science ®Google Scholar
• Dubrovska A, Kanamoto T, Lomnytska M, Heldin C H, Volodko N, Souchelnytskyi S. TGFbeta1/Smad3 counteracts BRCA1-dependent repair of DNA damage. Oncogene 2005; 24: 2289–2297
   PubMed Web of Science ®Google Scholar
• Ehrhart E J, Carroll A, Segarini P, Tsang ML-S, Barcellos-Hoff M H. Latent transforming growth factor-b activation in situ: Quantitative and functional evidence following low dose irradiation. Journal of the Federation of American Societies for Experimental Biology Journal 1997; 11: 991–1002
   PubMed Web of Science ®Google Scholar
• Erickson A C, Barcellos-Hoff M H. The not-so innocent bystander: Microenvironment as a target of cancer therapy. Expert Opinion on Therapeutic Targets 2003; 7: 71–88
   PubMed Web of Science ®Google Scholar
• Ewan K B, Henshall-Powell R L, Ravani S A, Pajares M J, Arteaga C L, Warters R L, Akhurst R J, Barcellos-Hoff M H. Transforming growth factor-b1 mediates cellular response to DNA damage in situ. Cancer Research 2002; 62: 5627–5631
   PubMed Web of Science ®Google Scholar
• Flanders K C, Major C D, Arabshahi A, Aburime E E, Okada M H, Fujii M, Blalock T D, Schultz G S, Sowers A, Anzano M A, Mitchell J B, Russo A, Roberts A B. Interference with transforming growth factor-{beta}/Smad3 signaling results in accelerated healing of wounds in previously irradiated skin. American Journal of Pathology 2003; 163: 2247–2257
   PubMed Web of Science ®Google Scholar
• Hirohashi S, Kanai Y. Cell adhesion system and human cancer morphogenesis. Cancer Science 2003; 94: 575–581
   PubMed Web of Science ®Google Scholar
• Jobling M F, Mott J D, Finnegan M, Erickson A C, Taylor S E, Ledbetter S, Barcellos-Hoff M H. Isoform specificity of redox-mediated TGF-b activation. Radiation Research 2006; 166: 839–848
   PubMed Web of Science ®Google Scholar
• Kaartinen V, Voncken J W, Shuler C, Warburton D, Bu D, Heisterkamp N, Groffen J. Abnormal lung development and cleft palate in mice lacking TGF-b3 indicates defects of epithelial-mesenchymal interaction. Nature Genetics 1995; 11: 415–421
   PubMed Web of Science ®Google Scholar
• Kanamoto T, Hellman U, Heldin C H, Souchelnytskyi S. Functional proteomics of transforming growth factor-beta1-stimulated Mv1Lu epithelial cells: Rad51 as a target of TGFbeta1-dependent regulation of DNA repair. Embo Journal 2002; 21: 1219–1230
   PubMed Web of Science ®Google Scholar
• Kirshner J, Jobling M F, Pajares M J, Ravani S A, Glick A, Lavin M, Koslov S, Shiloh Y, Barcellos-Hoff M H. Inhibition of TGFb1 signaling attenuates ATM activity in response to genotoxic stress. Cancer Research 2006; 66: 10861–10868
   PubMed Web of Science ®Google Scholar
• Kong F-M, Anscher M S, Murase T, Abbott B D, Iglehart J D, Jirtle R L. Elevated plasma transforming growth factor-b1 levels in breast cancer patients decrease after surgical removal of tumor. Annals of Surgery 1995; 222: 155–162
   PubMed Web of Science ®Google Scholar
• Kozlov S, Gueven N, Keating K, Ramsay J, Lavin M F. ATP activates Ataxia-Telangiectasia Mutated (ATM) in vitro. Importance of autophosphorylation. Journal of Biological Chemistry 2003; 278: 9309–9317
   PubMed Web of Science ®Google Scholar
• Kulkarni A B, Huh C G, Becker D, Geiser A, Lyght M, Flanders K C, Roberts A B, Sporn M B, Ward J M, Karlsson S. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proceedings of the National Academy of Sciences USA 1993; 90: 770–774
   PubMed Web of Science ®Google Scholar
• Lahm A, Uhl M, Lehr H A, Ihling C, Kreuz P C, Haberstroh J. Photoshop-based image analysis of canine articular cartilage after subchondral damage. Archives of Orthopaedic and Trauma Surgery 2004; 124: 431–436
   PubMed Web of Science ®Google Scholar
• Liu P, Menon K, Alvarez E, Lu K, Teicher B A. Transforming growth factor-beta and response to anticancer therapies in human liver and gastric tumors in vitro and in vivo. International Journal of Oncology 2000; 16: 599–610
   PubMed Web of Science ®Google Scholar
• Martin M, Lefaix J, Delanian S. TGF-beta1 and radiation fibrosis: A master switch and a specific therapeutic target?. International Journal of Radiation Oncology, Biology, Physics 2000; 47: 277–290
   PubMed Web of Science ®Google Scholar
• Miyaki M, Kuroki T. Role of Smad4 (DPC4) inactivation in human cancer. Biochemical and Biophysical Research Communications 2003; 306: 799–804
   PubMed Web of Science ®Google Scholar
• Moran J M, Elshaikh M A, Lawrence T S. Radiotherapy: What can be achieved by technical improvements in dose delivery?. The Lancet Oncology 2005; 6: 51–58
   PubMed Web of Science ®Google Scholar
• Muraoka R S, Dumont N, Ritter C A, Dugger T C, Brantley D M, Chen J, Easterly E, Roebuck L R, Ryan S, Gotwals P J, Koteliansky V, Arteaga C L. Blockade of TGF-{beta} inhibits mammary tumor cell viability, migration, and metastases. Journal of Clinical Investigation 2002; 109: 1551–1559
   PubMed Web of Science ®Google Scholar
• Muraoka-Cook R S, Kurokawa H, Koh Y, Forbes J T, Roebuck L R, Barcellos-Hoff M H, Moody S E, Chodosh L A, Arteaga C L. Conditional overexpression of active transforming growth factor b accelerates metastases of transgenic mammary tumors. Cancer Research 2004; 64: 9002–9011
   PubMed Web of Science ®Google Scholar
• Ohmori T, Yang J L, Price J O, Arteaga C L. Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. Experimental Cell Research 1998; 245: 350–359
   PubMed Web of Science ®Google Scholar
• Portress D I, Bauer G, Hill M A, O'Neill P. Low-dose irradiation of nontransformed cells stimulates the selective removal of precancerous cells via intercellular induction of apoptosis. Cancer Research 2007; 67: 1246–1253
   PubMed Web of Science ®Google Scholar
• Pociask D A, Sime P J, Brody A R. Asbestos-derived reactive oxygen species activate TGF-beta1. Laboratory Investigation 2004; 84: 1013–1023
   PubMed Web of Science ®Google Scholar
• Rabbani Z N, Anscher M S, Zhang X, Chen L, Samulski T V, Li C Y, Vujaskovic Z. Soluble TGFbeta type II receptor gene therapy ameliorates acute radiation-induced pulmonary injury in rats. International Journal of Radiation Oncology, Biology, Physics 2003; 57: 563–572
   PubMed Web of Science ®Google Scholar
• Rifkin D. Latent Transforming Growth Factor-b (TGF-b) binding proteins: Orchestrators of TGF-b availability. Journal of Biological Chemistry 2005; 280: 7409–7412
   PubMed Web of Science ®Google Scholar
• Sanford L P, Ormsby I, Gittenberger-de Groot A C, Sariola H, Friedman R, Boivin G P, Cardell E L, Doetschman T. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 1997; 124: 2659–2670
   PubMed Web of Science ®Google Scholar
• Sawyer J S, Anderson B D, Beight D W, Campbell R M, Jones M L, Herron D K, Lampe J W, McCowan J R, McMillen W T, Mort N, Parsons S, Smith E CR, Vieth M, Weir L C, Yan L, Zhang F, Yingling J M. Synthesis and activity of New Aryl- and Heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-Type I receptor kinase domain. Journal of Medicinal Chemistry 2003; 46: 3953–3956
   PubMed Web of Science ®Google Scholar
• Shiloh Y. ATM: Sounding the double-strand break alarm. Cold Spring Harbor Symposium on Quantitative Biology 2000; 65: 527–533
   PubMedGoogle Scholar
• Siegel P M, Shu W, Cardiff R D, Muller W J, Massague J. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proceedings of the National Academy of Sciences USA 2003; 100: 8430–8435
   PubMed Web of Science ®Google Scholar
• Stoika R, Yakymovych M, Souchelnytskyi S, Yakymovych I. Potential role of transforming growth factor beta1 in drug resistance of tumor cells. Acta Biochimica Polonica 2003; 50: 497–508
   PubMed Web of Science ®Google Scholar
• Suardet L, Li C, Little J B. Radio-induced modulation of transforming growth factor beta1 sensitivity in a p53 wild-type human colorectal-cancer cell line. International Journal of Cancer 1996; 68: 126–131
   PubMed Web of Science ®Google Scholar
• Tang B, Vu M, Booker T, Santner S J, Miller F R, Anver M R, Wakefield L M. TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. Journal of Clinical Investigation 2003; 112: 1116–1124
   PubMed Web of Science ®Google Scholar
• Teicher B A. Malignant cells, directors of the malignant process: Role of transforming growth factor-beta. Cancer Metastasis Reviews 2001; 20: 133–143
   PubMed Web of Science ®Google Scholar
• Teicher B A, Holden S A, Ara G, Chen G. Transforming growth factor-beta in in vivo resistance. Cancer Chemotherapy and Pharmacology 1996; 37: 601–609
   PubMed Web of Science ®Google Scholar
• Teicher B A, Ikebe M, Ara G, Keyes S R, Herbst R S. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: Reversal by decorin. In Vivo 1997; 11: 463–472
   PubMed Web of Science ®Google Scholar
• Wiegman E M, Blaese M A, Loeffler H, Coppes R P, Rodemann H P. TGFbeta-1 dependent fast stimulation of ATM and p53 phosphorylation following exposure to ionizing radiation does not involve TGFbeta-receptor I signalling. Radiotherapy and Oncology 2007; 83: 289–295
   PubMed Web of Science ®Google Scholar
• Xavier S, Piek E, Fujii M, Javelaud D, Mauviel A, Flanders K C, Samuni A M, Felici A, Reiss M, Yarkoni S, Sowers A, Mitchell J B, Roberts A B, Russo A. Amelioration of radiation-induced fibrosis: Inhibition of Transforming Growth Factor-{beta} signaling by halofuginone. Journal of Biological Chemistry 2004; 279: 15167–15176
   PubMed Web of Science ®Google Scholar
• Xie W, Mertens J C, Reiss D J, Rimm D L, Camp R L, Haffty B G, Reiss M. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: A tissue microarray study. Cancer Research 2002; 62: 497–505
   PubMed Web of Science ®Google Scholar
• Xu Y, Baltimore D. Dual roles of ATM in the cellular response to radiation and in cell growth control. Genes and Development 1996; 10: 2401–2410
   PubMed Web of Science ®Google Scholar
• Yingling J M, Blanchard K L, Sawyer J S. Development of TGF-[beta] signalling inhibitors for cancer therapy. Nature Reviews Drug Discovery 2004; 3: 1011–1022
   PubMed Web of Science ®Google Scholar